Deerfield Management is putting up $2bn for early-stage life sciences research through to 2030, but what does its involvement mean for its partner universities?
We certainly have come a long way since Martin Cline’s disastrous gene transfer experiment at University of California, Los Angeles ignited a public scandal forty years ago. Cline injected recombinant DNA to treat two patients at foreign clinics with terminal hereditary blood disorders, however, the ethical debate remained in its infancy. US guidelines explicitly forbade…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
